EE333 Budget Impact of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the U.S.: An Updated Analysis
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.632
https://www.valueinhealthjournal.com/article/S1098-3015(24)00747-2/fulltext
Title :
EE333 Budget Impact of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the U.S.: An Updated Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00747-2&doi=10.1016/j.jval.2024.03.632
First page :
Section Title :
Open access? :
No
Section Order :
10107